Akebia Therapeutics (AKBA) Change in Receivables (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Change in Receivables of $15.7 million for Q1 2026, down 43.66% year-over-year from $27.9 million in Q1 2025, and up 182.23% quarter-over-quarter from -$19.1 million in Q4 2025.
Akebia Therapeutics (AKBA) Change in Receivables (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Change in Receivables for 13 consecutive years, with $15.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 43.66% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $2.0 million (down 94.59% YoY), while the FY2025 annual figure was $14.1 million, up 449.53% from the prior year.
- Change in Receivables improved to $15.7 million in Q1 2026 per AKBA's latest filing, from -$19.1 million in the prior quarter.
- Across five years, Change in Receivables topped out at $27.9 million in Q1 2025 and bottomed at -$58.7 million in Q3 2022.
- Historically, Change in Receivables has averaged $794647.1 across 5 years, with a median of $3.1 million in 2024.
- Annual changes were most pronounced in 2022 — Change in Receivables soared 7399.56% — and 2025, when it tumbled 721.28%.
- Akebia Therapeutics' Change in Receivables stood at $17.0 million in 2022, then slipped by 1.86% to $16.7 million in 2023, then plunged by 81.59% to $3.1 million in 2024, then sank by 721.28% to -$19.1 million in 2025, then soared by 182.23% to $15.7 million in 2026.
- Business Quant data shows AKBA's Change in Receivables at $15.7 million in Q1 2026, -$19.1 million in Q4 2025, and -$6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | -9.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.03 Mn |
| Jun 30, 2026 | -9.03 Mn |
| Mar 31, 2026 | 15.70 Mn |
| Mar 31, 2026 | 15.70 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Dec 31, 2025 | -19.10 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Sep 30, 2025 | -6.16 Mn |
| Jun 30, 2025 | 11.53 Mn |
| Jun 30, 2025 | 11.53 Mn |
| Mar 31, 2025 | 27.87 Mn |
| Mar 31, 2025 | 27.87 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Sep 30, 2024 | 2.41 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Jun 30, 2024 | 3.15 Mn |
| Mar 31, 2024 | -12.67 Mn |
| Mar 31, 2024 | -12.67 Mn |